Live-cell microscopy reveals small molecule inhibitor effects on MAPK pathway dynamics

Daniel J Anderson1, Jenni K Durieux, Kyung Song

  • 1Department of Cell Regulation, Genentech, Inc, South San Francisco, California, United States of America.

Plos One
|August 11, 2011
PubMed

Insights

Small molecule kinase inhibitors targeting the mitogen-activated protein kinase (MAPK) pathway can paradoxically activate it. Our study reveals how Raf and Mek inhibitors affect MAPK signaling and CRaf localization in live cells.

Area of Science:

  • Cellular biology
  • Molecular oncology
  • Drug discovery

Background:

  • The mitogen-activated protein kinase (MAPK) pathway is frequently altered in human cancers, making it a key target for therapeutic interventions.
  • Recent findings indicate that ATP-competitive Raf inhibitors can paradoxically activate the MAPK pathway through Raf kinase priming, necessitating a deeper understanding of signaling dynamics under inhibitor treatment.
  • Understanding these complex signaling events is crucial for developing effective targeted therapies.

Purpose of the Study:

  • To develop and apply advanced live-cell imaging assays for simultaneous tracking of multiple MAPK pathway components (KRas, CRaf, Mek1, Erk2).
  • To systematically investigate the effects of small molecule inhibitors on MAPK signaling, both as single agents and in combination.
  • To elucidate the mechanisms underlying MAPK pathway activation and CRaf translocation induced by Raf and Mek inhibitors.

Main Methods:

  • Utilized improved cell-line engineering, automated image acquisition, and advanced image analysis techniques.
  • Developed assays for simultaneous identification and localization of KRas, CRaf, Mek1, and Erk2 within live cells.
  • Conducted systematic studies on the impact of various small molecule inhibitors on MAPK pathway components.

Main Results:

  • Observed that both Raf inhibitor priming and the release from negative feedback by Mek/Erk inhibitors promote CRaf translocation to the plasma membrane through additive mechanisms.
  • Demonstrated differential inhibition and activation of Erk by Raf inhibitors AZD628 and GDC0879, respectively, based on activation and subcellular localization.
  • Showcased the additive nature of pathway activation mechanisms induced by Raf and Mek/Erk inhibitors.

Conclusions:

  • The developed live-cell assays provide valuable insights into MAPK signaling dynamics in response to small molecule inhibitors.
  • Findings highlight the complex interplay of pathway components and feedback loops under inhibitor pressure.
  • These assays are critical for evaluating the efficacy of current and future MAPK-targeted therapies, including combination strategies.